Additional European Equity News - 17th August 2026
AstraZeneca discontinued its eVOLVE-Lung02 trial but reported success for Enhertu in DESTINY-Lung04. Hiscox completed a buyback tranche, and Partners Group secured a $1 billion private credit mandate in Asia.
News detail
AstraZeneca (AZN LN) - Co. announces that it is discontinuing the eVOLVE-Lung02 Phase 3 trial evaluating volrustomig in combination with chemotherapy as a 1st-line therapy, based on the recommendation of the IDMC following a planned review of trial data. The IDMC concluded that the volrustomig combination was unlikely to meet either of the dual primary endpoints of progression-free survival or overall survival. In other news, its Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial. (AstraZeneca) Hiscox (HSX LN) - Co. announces that it has completed the initial tranche of its share buyback programme. (Hiscox) Partners Group (PGHN SW) - Co. closes a new USD 1bln private credit mandate with a major institutional investor in Asia. (EQS)
Related stocks
1 stocksWhat do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.